Any current/future new fundraising through debt or equity?

There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript. The company reported that it has not utilized any working capital limits in the last 9 months except for letters of credit and bank guarantees, indicating stable liquidity. Capex plans include approximately INR 15 crores for the remainder of FY26 (primarily maintenance and small projects), with no immediate mention of the need for additional funding. The company plans significant capex at the Patalganga site starting next year, potentially around INR 40-50 crores initially,

Any current/future capex/capital investment/strategic investment?

Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility. Remaining FY26 capex expected around INR 15 crores for maintenance and small projects like Riboflavin block and formulation plant needs. Planned ground-breaking for Patalganga site utilities block in coming year with initial INR 40-50 crores investment. Future plan includes setting up either an API or formulation facility at Patalganga targeted around FY29. Ambernath facility capex estimated between INR 140-160 crores; commercial revenue expected from Q4 FY26, EBITDA positive around Q3 FY27. Isambe site blueprint finalizati

Future growth expectations in sales/revenue/volumes?

Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond. Expectation to achieve INR1,000 crores revenue milestone in FY27 supported by: - Scale-up of existing product basket in regulated markets. - Launch of 3 to 4 new products per year, with new products contributing around 10% of revenue in 2-3 years. - Commercial revenue from the newly commissioned Ambernath finished formulation facility starting Q4 FY26, with full impact in FY27. Backward integration is increasing, currently at 74%, expected to rise to 80-82% soon. Long-term aim includes healthy growth

Future growth expectations in earnings/operating earnings/profits/EPS?

Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products. Revenue is expected to reach around INR1,000 crores in FY27, driven by core therapeutic segments and the Ambernath facility. EBITDA margins are maintained between 33% to 35%. Ambernath facility is expected to start commercial revenue in Q4 FY26, achieving EBITDA positivity around Q3 FY27. New product launches (3-4 annually) are expected to contribute about 10% of revenues in 2-3 years. Backward integration will increase from 74% to 80-82%, sup

Current/ Expected Orderbook/ Pending Orders?

The company has good visibility on the order book for Q4 FY26, confident of achieving the revenue targets. Supriya Lifescience is not quantifying the exact order book but confirms firm visibility and volume commitments from customers. For the ATS-8 product for FY27, they have identified annual consumption for end users, with many in the signing stage of volume commitments. Large contracts for CDMO/CMO are under discussion, with term sheets being signed; announcements expected in coming quarters. Some shipments intended for late December were delayed due to holidays, causing spillover of busine

IN US

Sale is live|00:00:00left today

Supriya Lifescience LtdQ4 FY27Pharmaceuticals & Biotechnology

Supriya Lifescience Ltd Q4 FY27 Earnings Call Analysis

Revenue, margin, capex, fundraise and order book outlook from management commentary.

Price: ₹928P/E: 29.9Market Cap: ₹5.5K CrSector: Pharmaceuticals & Biotechnology

Management growth scorecard

Revenue

Category 2

Margin

Category 3

Fundraise

N/A

Order

N/A

Capex

Yes

1 of 3 growth signals are positive — mixed outlook.

Full analysis

Revenue guidance

Category 2

→Supriya Lifescience targets approximately 20% annual revenue growth for FY27 and beyond.
→Expectation to achieve INR1,000 crores revenue milestone in FY27 supported by:
→ - Scale-up of existing product basket in regulated markets.
→ - Launch of 3 to 4 new products per year, with new products contributing around 10% of revenue in 2-3 years.
→ - Commercial revenue from the newly commissioned Ambernath finished formulation facility starting Q4 FY26, with full impact in FY27.
→Backward integration is increasing, currently at 74%, expected to rise to 80-82% soon.
→Long-term aim includes healthy growth via new products, contract manufacturing, and CDMO pipeline.
→Certain large product volumes (e.g., cardiovascular product visibility of 250-300 tons) are expected to fully realize in FY27.
→CDMO/CMO and new products combined are targeted to contribute 20% of revenues in medium term.

Margin guidance

Category 3

→Supriya Lifescience targets approximately 20% annual revenue growth for FY27, supported by new product launches and scaling existing products.
→Revenue is expected to reach around INR1,000 crores in FY27, driven by core therapeutic segments and the Ambernath facility.
→EBITDA margins are maintained between 33% to 35%.
→Ambernath facility is expected to start commercial revenue in Q4 FY26, achieving EBITDA positivity around Q3 FY27.
→New product launches (3-4 annually) are expected to contribute about 10% of revenues in 2-3 years.
→Backward integration will increase from 74% to 80-82%, supporting margin sustainability.
→The company plans to leverage CDMO/CMO growth as part of its strategy, contributing toward the 20% combined growth target with new products.
→Strong order book visibility and export markets (LatAm, Europe) will support consistent growth.

3 more insights locked — sign up free to unlock

Fundraise plans

→There is no explicit mention of any current or planned new fundraising through debt or equity in the provided transcript.
→The company reported that it has not utilized any working capital limits in the last 9 months except for letters of credit and bank guarantees, indicating stable liquidity.
→Capex plans include approximately INR 15 crores for the remainder of FY26 (primarily maintenance and small projects), with no immediate mention of the need for additional funding.
→The company plans significant capex at the Patalganga site starting next year, potentially around INR 40-50 crores initially, but funding sources or fundraising plans for this are not discussed.
→Overall, the management has not indicated any intention to raise new equity or debt in the near term based on the available information.

Order book

→The company has good visibility on the order book for Q4 FY26, confident of achieving the revenue targets.
→Supriya Lifescience is not quantifying the exact order book but confirms firm visibility and volume commitments from customers.
→For the ATS-8 product for FY27, they have identified annual consumption for end users, with many in the signing stage of volume commitments.
→Large contracts for CDMO/CMO are under discussion, with term sheets being signed; announcements expected in coming quarters.
→Some shipments intended for late December were delayed due to holidays, causing spillover of business into Q4.
→The company is confident in its ability to achieve approximately 20% annual revenue growth based on current order book and pipeline visibility.

Capex plans

Yes

→Capex for 9MFY26 was INR 71 crores, mainly for the Ambernath facility.
→Remaining FY26 capex expected around INR 15 crores for maintenance and small projects like Riboflavin block and formulation plant needs.
→Planned ground-breaking for Patalganga site utilities block in coming year with initial INR 40-50 crores investment.
→Future plan includes setting up either an API or formulation facility at Patalganga targeted around FY29.
→Ambernath facility capex estimated between INR 140-160 crores; commercial revenue expected from Q4 FY26, EBITDA positive around Q3 FY27.
→Isambe site blueprint finalization underway; site possession obtained after environmental clearance, with construction expected to start soon.
→Strategic focus on capacity enhancements, new R&D facilities, and backward integration to support growth above 20%.

How does Supriya Lifescience Ltd rank vs peers in Pharmaceuticals & Biotechnology?

Pro feature

1Supriya Lifescience Ltd

Rev 2Mar 3

See full Pharmaceuticals & Biotechnology sector rankings

Want more stocks like Supriya Lifescience Ltd?

Build an AI portfolio filtered by sector, market cap, and growth rank. Takes 2 minutes.

Build my portfolio